The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

Severe acute respiratory syndrome coronavirus 2 is responsible for coronavirus disease
2019 (COVID‐19). While COVID‐19 is often benign, a subset of patients develops severe …

Summary Coronavirus disease 2019 (COVID-19) currently has few effective treatments.
Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important …

The current coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has had
devastating effects on the global health and economic system. The cellular and molecular …

Lipoxygenases (LOXs) are lipid metabolizing enzymes that catalyze the di-oxygenation of
polyunsaturated fatty acids to generate active eicosanoid products. 12-lipoxygenases (12 …

COVID-19 is characterized by two major clinical phases, the SARS-CoV-2 infection of target
cells and tissues, and a deep inflammatory state, known as “cytokine storm”, caused by …

To develop antiviral therapeutics against human coronavirus (HCoV) infections, suitable
coronavirus drug targets and corresponding lead molecules must be urgently identified …

The successful application of chimeric antigen receptor (CAR) T cells for the treatment of
relapsed and refractory B-cell malignancies has ushered in a new frontier for the …

Abstract Purpose of Review Patients on disease-modifying anti-rheumatic drugs (DMARDs)
remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several …